Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;28(12):3301-3314.
doi: 10.1007/s00198-017-4189-7. Epub 2017 Sep 15.

Inflammatory Diseases and Bone Fragility

Affiliations
Review

Inflammatory Diseases and Bone Fragility

K Briot et al. Osteoporos Int. .

Abstract

Systemic osteoporosis and increased fracture rates have been described in chronic inflammatory diseases such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, inflammatory bowel diseases, and chronic obstructive pulmonary disease. Most of these patients receive glucocorticoids, which have their own deleterious effects on bone. However, the other main determinant of bone fragility is the inflammation itself, as shown by the interactions between the inflammatory mediators, the actors of the immune system, and the bone remodelling. The inflammatory disease activity is thus on top of the other well-known osteoporotic risk factors in these patients. Optimal control of inflammation is part of the prevention of osteoporosis, and potent anti-inflammatory drugs have positive effects on surrogate markers of bone fragility. More data are needed to assess the anti-fracture efficacy of a tight control of inflammation in patients with a chronic inflammatory disorder. This review aimed at presenting different clinical aspects of inflammatory diseases which illustrate the relationships between inflammation and bone fragility.

Keywords: Bone densitometry; Fracture; Inflammation; Osteoporosis.

Similar articles

  • Inflammatory rheumatic disorders and bone.
    Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF. Bultink IE, et al. Curr Rheumatol Rep. 2012 Jun;14(3):224-30. doi: 10.1007/s11926-012-0252-8. Curr Rheumatol Rep. 2012. PMID: 22477520 Free PMC article. Review.
  • Biologic therapies and bone loss in rheumatoid arthritis.
    Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE; IOF Chronic Inflammation and Bone Structure (CIBS) Working Group. Zerbini CAF, et al. Osteoporos Int. 2017 Feb;28(2):429-446. doi: 10.1007/s00198-016-3769-2. Epub 2016 Oct 31. Osteoporos Int. 2017. PMID: 27796445 Review.
  • Skeletal complications of rheumatoid arthritis.
    Heinlen L, Humphrey MB. Heinlen L, et al. Osteoporos Int. 2017 Oct;28(10):2801-2812. doi: 10.1007/s00198-017-4170-5. Epub 2017 Aug 4. Osteoporos Int. 2017. PMID: 28779302 Review.
  • Bone remodelling in inflammatory arthritis.
    Goldring SR, Purdue PE, Crotti TN, Shen Z, Flannery MR, Binder NB, Ross FP, McHugh KP. Goldring SR, et al. Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii52-5. doi: 10.1136/annrheumdis-2012-202199. Epub 2012 Dec 19. Ann Rheum Dis. 2013. PMID: 23253928 Review.
  • Osteoporosis and inflammation.
    Lacativa PG, Farias ML. Lacativa PG, et al. Arq Bras Endocrinol Metabol. 2010 Mar;54(2):123-32. doi: 10.1590/s0004-27302010000200007. Arq Bras Endocrinol Metabol. 2010. PMID: 20485900 Review.
See all similar articles

Cited by 18 articles

See all "Cited by" articles

References

    1. J Bone Miner Res. 2000 Jan;15(1):2-12 - PubMed
    1. Gastroenterol Rep (Oxf). 2013 Nov;1(3):159-65 - PubMed
    1. Osteoporos Int. 2011 May;22(5):1431-9 - PubMed
    1. Lupus. 2005;14(2):106-12 - PubMed
    1. Arthritis Rheum. 2007 Dec;56(12):4104-12 - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback